1447 / 1542
TARGIT clinical trials
•
Phase 3 RCT compared single 20Gy TARGIT with whole
breast irradiation
•
Over 3,500 patients recruited from 33 centres
•
Entry if > 45 years and solitary cancer < 3.5cm diameter
•
Additional EBRT given in 1 in 5 if histology more adverse
(risk stratified approach)
•
Recurrence 3.3% TARGIT vs. 1.3% EBRT
•
Controversy about statistical analysis and interpretation
Vaidya et al. Lancet (2014) 383: 603-13